BRD5631 is an autophagy enhancer, enhances autophagy through an mTOR-independent pathway. BRD5631 affects several cellular disease phenotypes previously linked to autophagy, including protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production. BRD5631 can serve as a valuable tool for studying the role of autophagy in the context of cellular homeostasis and disease. [1].

BRD5631 (10 μM, 48 hours) results in increased levels of LC3-II in HeLa cells. BRD5631 stimulates formation of new autophagosomes, which is consistent with its ability to increase numbers of autolysosomes in the mCherry-GFP-LC3 assay [1]. BRD5631 does not enhance autophagy by directly inhibiting mTOR or the mTOR signaling pathway. BRD5631 suppressed IL-1β secretion in an autophagy-dependent manner [1]. Cell Viability Assay [1] Cell Line: HeLa cells. Concentration: 10 μM. Incubation Time: 48 hours. Result: Led to increased levels of LC3-II.